地氯雷他定配合免疫疗法治疗自身免疫性荨麻疹疗效分析

目的观察地氧雷他定配合免疫疗法治疗自身免疫性荨麻疹的有效性和安全性。方法采用随机、双盲对照法．共治疗75例患者。试验组40例。口服地氯雷他定5mg，1日1次．匹多莫德0．4g，1日2次和雷公藤多甙20mg，1日3次；对照组35例，口服地氯雷他定5mg，每天1次，连用6周。两组病例均停药观察12周。结果试验组有效率为87．37％，对照组有效率65．71％，两组疗效有显著性差异（P〈0．01）；停药后随访3个月。试验组复发率16．67％，对照组为66．67％，两组复发率有显著性差异（P〈0．01）：试验组不良反应发生率为5．00％，对照组2.89％。结论地氯雷他定配合免疫疗法治疗自身免疫性荨麻疹的近期疗效和远期疗效均优于单用地氯雷他定，复发率较低，耐受性好。无严重不良反应。

Investigation on the therapeutic effect of desloratadine combined immuned treatment in treatment of autoimmune urticaria

OBJECTIVE To evaluate efficacy and safety of desloratadine combined immuned treatment in the treatment of autoimmune urticaria. METHODS A randomized, open-label, parallel comparative clinical trial was conducted in 75 patients. They were divided into study group and control group. The patients in study group were treated with desloratadine and immuned treatment. The patients in control group were treated with desloratadine only. The recurrent rates were also recorded 12 week after discontinuation of the treatment. RESULTS The effi- cant rates of study group and control group were 87.5 %, 65.7 % respectively. There was significantly statistical difference between two groups. CONCLUSIONS Desloratadine combined immuned treatment was high clinical efficacy and low recurrent rate in the treatment of autoimmune urticaria.